Accueil   Diary - News   All news Positifs results for Imaxio clinical trial

Positifs results for Imaxio clinical trial

Imaxio announces the publication of the results of a phase I trial of MVA85A-IMX313, the first human clinical trial using the IMX313 technology

 

 

The vaccine candidate has proven to be safe in healthy patients in this dose escalation study. These results confirm that IMX313, Imaxio’s antigen re-engineering technology, is safe in humans

 

 

Imaxio, a biotech company specialized in immunology, announces that the results of its tuberculosis vaccine phase I clinical trial have been published in the journal Vaccine. The trial, which was conducted by the Jenner Institute at Oxford University (UK), has proved that the vaccine candidate (and thus IMX313, Imaxio’s antigen re-engineering technology) is safe in humans. The study was performed in the UK and was led by Prof. Helen McShane from the Jenner Institute at Oxford University. 

 



Read the press release

 

 

 

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree